275 related articles for article (PubMed ID: 21502403)
1. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
[TBL] [Abstract][Full Text] [Related]
2. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
3. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.
Fiskus W; Hembruff SL; Rao R; Sharma P; Balusu R; Venkannagari S; Smith JE; Peth K; Peiper SC; Bhalla KN
Breast Cancer Res Treat; 2012 Sep; 135(2):433-44. PubMed ID: 22825030
[TBL] [Abstract][Full Text] [Related]
4. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors.
Whitecross KF; Alsop AE; Cluse LA; Wiegmans A; Banks KM; Coomans C; Peart MJ; Newbold A; Lindemann RK; Johnstone RW
Blood; 2009 Feb; 113(9):1982-91. PubMed ID: 19060243
[TBL] [Abstract][Full Text] [Related]
5. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
[TBL] [Abstract][Full Text] [Related]
6. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
Dai Y; Chen S; Venditti CA; Pei XY; Nguyen TK; Dent P; Grant S
Blood; 2008 Aug; 112(3):793-804. PubMed ID: 18505786
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
8. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
Muscal JA; Scorsone KA; Zhang L; Ecsedy JA; Berg SL
Invest New Drugs; 2013 Feb; 31(1):39-45. PubMed ID: 22669335
[TBL] [Abstract][Full Text] [Related]
9. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
[TBL] [Abstract][Full Text] [Related]
10. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.
Zhang X; Chen X; Lin J; Lwin T; Wright G; Moscinski LC; Dalton WS; Seto E; Wright K; Sotomayor E; Tao J
Oncogene; 2012 Jun; 31(24):3002-3008. PubMed ID: 22002311
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Son MP; Attkisson E; Dent P; Fisher RI; Friedberg JW; Grant S
Mol Cancer Ther; 2011 Sep; 10(9):1686-97. PubMed ID: 21750224
[TBL] [Abstract][Full Text] [Related]
14. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Ann Hematol; 2010 Nov; 89(11):1081-7. PubMed ID: 20563869
[TBL] [Abstract][Full Text] [Related]
16. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
Chowdhury A; Chowdhury S; Tsai MY
Leuk Lymphoma; 2012 Mar; 53(3):462-71. PubMed ID: 21879811
[TBL] [Abstract][Full Text] [Related]
17. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
[TBL] [Abstract][Full Text] [Related]
18. Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors.
Ierano C; Chakraborty AR; Nicolae A; Bahr JC; Zhan Z; Pittaluga S; Bates SE; Robey RW
Cell Cycle; 2013 Sep; 12(17):2829-38. PubMed ID: 23966164
[TBL] [Abstract][Full Text] [Related]
19. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
Morelli MP; Tentler JJ; Kulikowski GN; Tan AC; Bradshaw-Pierce EL; Pitts TM; Brown AM; Nallapareddy S; Arcaroli JJ; Serkova NJ; Hidalgo M; Ciardiello F; Eckhardt SG
Clin Cancer Res; 2012 Feb; 18(4):1051-62. PubMed ID: 22173548
[TBL] [Abstract][Full Text] [Related]
20. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.
Kawano T; Horiguchi-Yamada J; Iwase S; Akiyama M; Furukawa Y; Kan Y; Yamada H
Anticancer Res; 2004; 24(5A):2705-12. PubMed ID: 15517875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
